Verve Therapeutics (VERV) IPO Opens 58% Higher

Today's IPO for Verve Therapeutics (NASDAQ: VERV) opened for trading at $30 after pricing 14,035,789 shares of its common stock at a price to the public of $19.00 per share.

J.P. Morgan, Jefferies, Guggenheim Securities and William Blair are acting as joint book-running managers for the offering.

Verve Therapeutics is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company’s initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol (LDL-C), a root cause of cardiovascular disease. Verve’s lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient’s risk for cardiovascular disease. VERVE-101, currently in IND-enabling studies, is being developed initially for the treatment of patients with heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease.

You May Also Be Interested In

• Anthropic CFO Krishna Rao is leading early IPO meetings with investors and has not discussed valuation - CNBC
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• OpenAI revenue chief quits after less than a year